Evidence map›Paper›PMID 28260096›Full record

ArticleMolecular medicine reports2017

Increased Δ133p53 mRNA in lung carcinoma corresponds with reduction of p21 expression.

Aikaterini Fragou, Georgios Tzimagiorgis, Christos Karageorgopoulos, Nikolaos Barbetakis, Axilleas Lazopoulos, Maria Papaioannou, Costas Haitoglou, Sofia Kouidou

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. The p53 Isoforms as Potential Biomarkers in Different Cancer Entities.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. p53 and its isoforms in DNA double-stranded break repair.Journal of Zhejiang University. Science. B · 2019
    Review
  12. A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.Mammalian genome : official journal of the International Mammalian Genome Society · 2018
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Aikaterini FragouLaboratory of Biological Chemistry, Medical Department, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Georgios TzimagiorgisLaboratory of Biological Chemistry, Medical Department, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Christos KarageorgopoulosLaboratory of Biological Chemistry, Medical Department, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Nikolaos BarbetakisDepartment of Thoracic Surgery, Theagenion Anticancer Hospital, Thessaloniki 54007, Greece.
Axilleas LazopoulosDepartment of Thoracic Surgery, Theagenion Anticancer Hospital, Thessaloniki 54007, Greece.
Maria PapaioannouLaboratory of Biological Chemistry, Medical Department, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Costas HaitoglouLaboratory of Biological Chemistry, Medical Department, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Sofia KouidouLaboratory of Biological Chemistry, Medical Department, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
Aristotle University of Thessaloniki · GRTheageneio General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modification of p53 expression levels and its principle apoptosis and cell cycle regulatory partners, mouse double minute 2 homolog (MDM‑2) and p21, has been previously reported in various types of cancer. In the current study, the expression of Δ133p53 isoforms was investigated in lung carcinomas with respect to the expression of the aforementioned genes. The expression of p53 full‑length transcript and Δ133p53 isoforms α, β and γ transcripts, MDM‑2 and p21 transcripts were determined by reverse transcription‑quantitative polymerase chain reaction, in total RNA isolated from 17 lung carcinoma specimens and 17 corresponding adjacent non‑cancerous tissues. RNA expression analysis was performed according to the Pfaffl equation and Rest tool using β‑actin as a reference gene. Detection of the above proteins was additionally performed by western blotting. Significant overexpression of the Δ133p53 mRNAs was observed in cancerous as compared with adjacent non‑cancerous tissues (3.94‑fold), whereas full‑length p53 and MDM‑2 expression exhibited a smaller, however significant, increase. The expression of the p21 transcript was significantly reduced in cancerous specimens. Δ133p53 and p21 expression levels varied in parallel, however were not significantly correlated. p53 full‑length protein expression observed by western blot analysis strongly varied from the Δ133p53 isoforms, however MDM‑2 protein isoforms were not detectable and p21 protein was more abundant in non‑cancerous tissues. In conclusion, Δ133p53 mRNA levels is suggested as a potentially useful marker of malignancy in lung cancer. The absence of Δ133p53 protein in lung carcinomas, which overexpress Δ133p53 transcripts, may indicate the role of the latter in post‑transcriptional regulation through RNA interference in the cell cycle and apoptosis.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedBlotting, WesternCyclin-Dependent Kinase Inhibitor p21FemaleHumansLung NeoplasmsMaleMiddle AgedProtein IsoformsProto-Oncogene Proteins c-mdm2Real-Time Polymerase Chain ReactionRNA, MessengerSmokingTumor Suppressor Protein p53Cyclin-Dependent Kinase Inhibitor p21Protein IsoformsProto-Oncogene Proteins c-mdm2RNA, MessengerTumor Suppressor Protein p53

Identifiers

PMID28260096
PMCPMC5364986
OpenAlexW2585295293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.